Surrozen Q2 2025: Progress in Eye Disease Therapies and Improved Financials

Surrozen reported Q2 2025 net income of $39.7mln, a significant turnaround from a net loss of $25.3mln in the same period last year. The company highlighted advancements in its ophthalmology pipeline, including the progress of lead candidates SZN-8141 and SZN-8143. Surrozen's cash position stood at $90.4mln as of June 30, 2025. The company plans to submit an Investigational New Drug application for SZN-8141 in 2026.

Surrozen, Inc. (NasdaqCM: SRZN) has reported its second-quarter 2025 financial results, showing a significant turnaround with a net income of $39.7 million, compared to a net loss of $25.3 million in the same period last year. The company's cash position stood at $90.4 million as of June 30, 2025.

Surrozen highlighted advancements in its ophthalmology pipeline, with progress on lead candidates SZN-8141 and SZN-8143 for retinal diseases. The company noted that it is on track to submit an Investigational New Drug (IND) application for SZN-8141 in 2026. Additionally, Surrozen announced the issuance of a U.S. patent for its SWAP™ technology, which strengthens its intellectual property for SZN-8141 and SZN-8143.

The company also appointed Dr. Daniel Chao as Vice President of Clinical Development, bringing extensive expertise in ophthalmology. This appointment, along with the formation of a Clinical Advisory Board, underscores Surrozen's commitment to advancing its ophthalmology pipeline and addressing unmet needs in retinal diseases.

Financially, Surrozen's second-quarter 2025 results were driven by a gain on change in fair value of tranche liability and other income. The company's operating expenses stood at $10.0 million, with an operating income of -$9.02 million.

Analysts remain optimistic about Surrozen's prospects. The current average analyst rating on the shares is "strong buy," with no "hold" or "sell" recommendations. The median 12-month price target for Surrozen Inc is $37.00, about 75.6% above its August 7 closing price of $9.03 [2].

Looking ahead, Surrozen is poised to continue its momentum in the ophthalmology sector, leveraging its proprietary technologies and strategic partnerships to advance its pipeline and potentially transform the treatment landscape for severe eye diseases.

References:
[1] https://www.marketscreener.com/news/surrozen-posts-q2-net-income-of-39-7-mln-ce7c5edddc80f524
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_PLX677F74:0-surrozen-posts-q2-net-income-of-39-7-mln/